Compounds, compositions, and methods for the treatment of infections caused by Acanthamoeba or Balamuthia mandrillaris trophozoites and/or cysts and for the disinfection of solids and/or liquids, such as medical and personal care items, for example contact lenses, that may harbor Acanthamoeba trophozoites and/or cysts are provided.

Compounds, compositions, and methods for the treatment of infections caused by Acanthamoeba or Balamuthia mandrillaris trophozoites and/or cysts and for the disinfection of solids and/or liquids, such as medical and personal care items, for example contact lenses, that may harbor Acanthamoeba trophozoites and/or cysts are provided.

An organic compound represented by the following formula [1] or [2]:

##STR00001##

wherein R.sub.1 to R.sub.22 independently denote a substituent selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted silyl group, a cyano group, a trifluoromethyl group, a substituted or unsubstituted aromatic hydrocarbon group, and a substituted or unsubstituted heterocyclic group, and R.sub.5 and R.sub.6, and/or R.sub.7 and R.sub.8 may be bonded together to form a ring structure.

Disclosed is an organic light emitting diode including a cathode, an anode, a light emitting layer provided between the cathode and the anode, a first electron transporting layer including a heterocyclic compound represented by Formula 1 and provided between the cathode and the light emitting layer, and a second electron transporting layer including a host material including one or two or more of compounds represented by Formulae 3 to 5 and one or two or more n-type dopants selected from alkali metals and alkaline earth metals and provided between the cathode and the first electron transporting layer: ##STR00001##

Disclosed is an organic light emitting diode including a cathode, an anode, a light emitting layer provided between the cathode and the anode, a first electron transporting layer including a heterocyclic compound represented by Formula 1 and provided between the cathode and the light emitting layer, and a second electron transporting layer including a host material including one or two or more of compounds represented by Formulae 3 to 5 and one or two or more n-type dopants selected from alkali metals and alkaline earth metals and provided between the cathode and the first electron transporting layer: ##STR00001##

Disclosed are compositions derived from 2,2′bisimidazoles building blocks and methods of making the same. The disclosed compositions are capable of withstanding temperatures up to 600° C. and substantially flame resistant.

Disclosed are compositions derived from 2,2′bisimidazoles building blocks and methods of making the same. The disclosed compositions are capable of withstanding temperatures up to 600° C. and substantially flame resistant.

An organic electroluminescence device according to an embodiment of the present disclosure includes a first electrode, a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one organic layer of the plurality of organic layers includes a polycyclic compound containing two aromatic 6-membered rings which are linked by a single bond, and a plurality of benzimidazole groups which are substituted at the two aromatic 6-membered rings, wherein each of the two aromatic 6-membered rings includes a carbon atom or a nitrogen atom as an atom for forming a ring.

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.